{
  "pmcid": "12346947",
  "sha256": "e5b16bc1077295ac2692a31a22ecf0b67781b05eae75d8bb1f89db1b29e2cc7a",
  "timestamp_utc": "2025-11-09T23:33:49.764685+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.584790975447913,
    "reading_ease": 41.357869940278704,
    "word_count": 274
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial of the AtriClip V-Clip for Left Atrial Appendage Exclusion"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Randomisation was conducted by providing a de-identified list of potential patients, which was then randomized and returned to the site for screening."
      },
      "Participants": {
        "score": 2,
        "evidence": "Patients aged â‰¥18 years who received V-shape AtriClip devices during non-emergent cardiac surgery were included."
      },
      "Intervention": {
        "score": 2,
        "evidence": "evaluated the long-term safety and performance of the epicardial V-shape AtriClip device."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary performance outcome was LAAE without residual left atrium-LAA communication, assessed by imaging at the last follow-up visit."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomisation was conducted by providing a de-identified list of potential patients, which was then randomized and returned to the site for screening."
      },
      "Blinding": {
        "score": 1,
        "evidence": "The study was unblinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 156 patients were enrolled from 11 U.S. centers between January 2022 and November 2022."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Of these, 155 patients were included in the intention-to-treat analysis, and 151 had evaluable imaging."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Primary performance in the intent-to-treat population was met, with 97% (95% CI 93.52%, 99.29%; p = 0.0001) complete LAAE."
      },
      "Harms": {
        "score": 1,
        "evidence": "One device-related SAE was reported, which resolved intraprocedurally."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "NCT05101993"
      },
      "Funding": {
        "score": 1,
        "evidence": "The study was funded by AtriCure, Inc."
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}